Literature DB >> 500746

A review of the behaviour of chondrosarcoma of bone.

N G Sanerkin, P Gallagher.   

Abstract

Sixty-two cases of chondrosarcoma of bone were reviewed and histologically graded as low, medium or high-grade tumours. After excluding patients dead from unrelated causes or lost to follow-up, forty cases were available for ten-year follow-up and fifty-eight for five-year follow-up. The rates of survival, recurrence and metastasis were analysed according to the histological grading. Recurrence was further analysed according to the adequacy of treatment. The results were compared with those previously reported in the literature. There was a ten-year survival rate of 58 per cent. Recurrence developed in 58 per cent and was uncontrollable in 29 per cent. The recurrence rate was 87 per cent with inadequate treatment and 15 per cent with adequate treatment. Recurrences outside the limb bones usually proved uncontrollable; recurrences in the limb bones were amenable to further, and if necessary repeated, operations. High-grade chondrosarcoma had a metastatic risk of 75 per cent and eventual mortality of 88 per cent. Medium-grade chondrosarcoma had a metastatic risk of 14 per cent and a mortality of 60 per cent. Low-grade chondrosarcoma had a metastatic risk of 5 per cent and a mortality of 29 per cent.

Entities:  

Mesh:

Year:  1979        PMID: 500746

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  20 in total

1.  Low-grade chondrosarcoma of bone: experiences from the Vienna Bone and Soft Tissue Tumour Registry.

Authors:  Philipp T Funovics; Joannis Panotopoulos; Manuel Sabeti-Aschraf; Farshid Abdolvahab; Josef M Funovics; Susanna Lang; Rainer I Kotz; Martin Dominkus
Journal:  Int Orthop       Date:  2010-08-28       Impact factor: 3.075

2.  [Therapy of enchondroma in long bones].

Authors:  H Steckel; M Oldenburg; R T Müller
Journal:  Unfallchirurg       Date:  2005-06       Impact factor: 1.000

3.  Does the survival between elderly and very elderly patients with different malignant primary bone tumours have no difference?

Authors:  Xiao-yang Li; Shuo Jie; Tao Xiao
Journal:  Int Orthop       Date:  2014-11-16       Impact factor: 3.075

4.  Curettage and cryosurgery for low-grade cartilage tumors is associated with low recurrence and high function.

Authors:  David G Mohler; Richard Chiu; David A McCall; Raffi S Avedian
Journal:  Clin Orthop Relat Res       Date:  2010-06-24       Impact factor: 4.176

5.  A reproducible and simple grading system for classical chondrosarcomas. Analysis of 35 chondrosarcomas and 16 enchondromas with emphasis on recurrence rate and radiological and clinical data.

Authors:  Heike Welkerling; Susanne Kratz; Volker Ewerbeck; Günter Delling
Journal:  Virchows Arch       Date:  2003-09-25       Impact factor: 4.064

6.  Phenolization and coralline hydroxyapatite grafting following meticulous curettage for the treatment of enchondroma of the hand. A case series of 82 patients with 5-year follow-up.

Authors:  Dimitrios Georgiannos; Vasilios Lampridis; Ilias Bisbinas
Journal:  Hand (N Y)       Date:  2015-03

7.  Extended intralesional treatment versus resection of low-grade chondrosarcomas.

Authors:  Chad Aarons; Benjamin K Potter; Sheila C Adams; J David Pitcher; H Thomas Temple
Journal:  Clin Orthop Relat Res       Date:  2009-01-14       Impact factor: 4.176

8.  No recurrences in selected patients after curettage with cryotherapy for grade I chondrosarcomas.

Authors:  Badio S Souna; Nicolas Belot; Hélène Duval; Frantz Langlais; Hervé Thomazeau
Journal:  Clin Orthop Relat Res       Date:  2010-01-07       Impact factor: 4.176

9.  Chondrosarcoma of the bones of the hand. Report of two cases.

Authors:  D Hernàndez-Vaquero; M Cima-Suarez; C Garcia-Pravia
Journal:  Arch Orthop Trauma Surg       Date:  1991       Impact factor: 3.067

10.  Chondrosarcoma of the calcaneum and massive soft tissue calcification in a patient with hereditary and acquired connective tissue diseases.

Authors:  I P Wicks; A Fleming
Journal:  Ann Rheum Dis       Date:  1987-04       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.